Compare ARK Space & Defense Innovation ETF (ARKX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Zimmer Biomet Holdings Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $31.8, while Zimmer Biomet Holdings Inc trades at $91.8 (market cap $17.67B). The key difference: Zimmer Biomet Holdings Inc pays a 1.05% dividend while ARK Space & Defense Innovation ETF pays none, and ARK Space & Defense Innovation ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ARKX | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $107.71 |
52-Week Low | $24.97 | $79.58 |
Market Cap | — | $17.67B |
Enterprise Value | — | $24.72B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Space Exploration & Innovation ETF (ARKX) trades at $32.05, down 0.82% today amid bearish technical signals. The ETF shows neutral oscillator readings but bearish moving averages, with key support at $32 and resistance at $33. Recent news highlights ARKX as a popular alternative to direct SpaceX investment, with the space economy reaching $500 billion in backlog according to 24/7 Wall Street (2026-07-06).
ARKX offers diversified exposure to the growing space sector without single-stock IPO risk. The ETF's higher volatility and expense ratio compared to traditional aerospace ETFs present both growth potential and increased risk. SpaceX's 8.31% weighting provides significant upside exposure but also concentration risk in a high-valuation name.
Zimmer Biomet (ZBH) trades at $91.34, up 2.36% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong profitability with a 70.03% gross margin and has beaten earnings estimates for three consecutive quarters. Recent developments include a $140M acquisition and plans to hire 500 employees in India, signaling growth initiatives.
Outlook is cautiously optimistic with a consensus price target of $98.00, though rising debt levels and competitive pressures pose risks. The stock offers steady dividend income and share repurchases, but investors should weigh execution risks against solid cash flow generation and market positioning in medical devices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
